{
    "clinical_study": {
        "@rank": "144877", 
        "arm_group": [
            {
                "arm_group_label": "Cycle 1", 
                "arm_group_type": "Experimental", 
                "description": "60mg"
            }, 
            {
                "arm_group_label": "Cycle 2", 
                "arm_group_type": "Experimental", 
                "description": "80mg dependent upon response to Cycle 1"
            }, 
            {
                "arm_group_label": "Cycle 2b", 
                "arm_group_type": "Experimental", 
                "description": "40mg dependent upon response to Cycle 1"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the response rate of patients with refractory,\n      relapsed or poor risk AML expressing FLT-3 activating mutations, when administered CEP-701\n      at a dosage of 60 mg 2 times a day."
        }, 
        "brief_title": "Open Study of CEP-701 in Patients With Refractory Acute Myeloid Leukemia With FLT-3 Mutation", 
        "completion_date": {
            "#text": "February 2003", 
            "@type": "Actual"
        }, 
        "condition": "Leukemia, Myeloid", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is an open-label study of CEP-701 in patients with refractory, relapsed, or poor risk\n      AML expressing FLT-3 activating mutations.  Patients who meet eligibility criteria will be\n      enrolled at a dosage of 60 mg orally 2 times a day for 28 days (1 cycle).  Upon completion\n      of cycle 1, the dosage may be increased to 80mg 2 times a day or decreased to 40 mg 2 times\n      a day, dependent upon response to 60 mg dosage."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "INCLUSION CRITERIA:\n\n          -  patient must have confirmed diagnosis of refractory or relapsed AML that expresses a\n             FLT-3 mutation\n\n          -  patient must have life expectancy of more than 2 months\n\n          -  patient must be fully recovered from reversible side effects of previous therapy for\n             cancer\n\n        EXCLUSION CRITERIA:\n\n          -  total bilirubin, ALT or AST greater than 2 times upper limit of normal\n\n          -  patient <65 years of age with estimated creatinine clearance less than 60 mL/min;\n             patient >65 years of age with serum creatinine > 1.5 times the upper limit of normal\n             (ULN)\n\n          -  received any investigational drug within past 4 weeks\n\n          -  GI disturbance/malabsorption that may affect absorption of CEP-701\n\n          -  HIV positive\n\n          -  received NSAID within prior 14 days\n\n          -  has active infection"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "37", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 7, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00030186", 
            "org_study_id": "C0701a/202/ON/US"
        }, 
        "intervention": [
            {
                "arm_group_label": "Cycle 1", 
                "description": "60mg orally 2 times a day for 28 days", 
                "intervention_name": "CEP-701 60mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cycle 2", 
                "description": "80mg 2 times a day, dependent upon response to cycle 1", 
                "intervention_name": "Cep-701 80mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cycle 2b", 
                "description": "40mg 2 times a day, dependent upon response to cycle 1", 
                "intervention_name": "Cep-701 40mg", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "AML", 
            "FLT-3 mutation"
        ], 
        "lastchanged_date": "August 14, 2012", 
        "number_of_arms": "3", 
        "official_title": "An Open-Label Study of CEP-701 in Patients With Refractory, Relapsed, or Poor Risk Acute Myeloid Leukemia Expressing FLT-3 Activating Mutations", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2003", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Response rate of patients with refactory, relapsed, or poor risk acute myeloid leukemia (AML) expressing Fms-like tyrosine kinase 3 (FLT-3) activating mutations. CR is defined as presence of less than 5% myeloblasts in bone marrow with normalized peripheral blood cell counts. HR is defined as a 50% or more decrease in the absolute number of peripheral blast count or at least a 50% reduction in bone marrow blasts.", 
            "measure": "Blood Samples and/or bone marrow assessments for complete remission (CR), complete tumor clearance (CTC), or hematologic response (HR) from bone marrow", 
            "safety_issue": "No", 
            "time_frame": "56 days"
        }, 
        "removed_countries": {
            "country": "United States"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00030186"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Response as defined by CR, CTC, or HR.", 
                "measure": "Number of days to response", 
                "safety_issue": "No", 
                "time_frame": "56 Days"
            }, 
            {
                "description": "Response as defined by CR, CTC, or HR.", 
                "measure": "Number of days to disease progression", 
                "safety_issue": "No", 
                "time_frame": "56 Days"
            }, 
            {
                "description": "The degree of inhibition of FLT-3 autophosphorylation measured in ex vivo bioassay plasma samples", 
                "measure": "Levels of FLT-3 phosphorylation inhibition in vivo", 
                "safety_issue": "No", 
                "time_frame": "56 Days"
            }
        ], 
        "source": "Teva Pharmaceutical Industries", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cephalon", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2002", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }, 
    "geocoordinates": {}
}